Humacyte (NASDAQ:HUMA) Given Buy Rating at BTIG Research

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a report released on Tuesday,Benzinga reports. They presently have a $2.00 target price on the stock. BTIG Research’s price target would suggest a potential upside of 86.92% from the company’s previous close.

Several other brokerages have also recently commented on HUMA. Benchmark raised their price target on shares of Humacyte to $2.00 and gave the company a “speculative buy” rating in a research report on Monday, June 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. HC Wainwright raised their price target on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.57.

Humacyte Stock Performance

NASDAQ:HUMA opened at $1.07 on Tuesday. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. The stock has a market capitalization of $237.56 million, a P/E ratio of -1.88 and a beta of 2.45. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.03. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.84.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. Equities research analysts forecast that Humacyte will post -0.3 EPS for the current year.

Insider Activity

In other news, Director Kathleen Sebelius acquired 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the acquisition, the director owned 148,025 shares of the company’s stock, valued at $130,262. This trade represents a 62.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Dale A. Sander sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of the company. UBS Group AG raised its stake in Humacyte by 48.8% during the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after acquiring an additional 976,275 shares in the last quarter. United Asset Strategies Inc. raised its stake in Humacyte by 13.5% during the 4th quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock worth $201,000 after acquiring an additional 25,000 shares in the last quarter. SG Americas Securities LLC raised its stake in Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after acquiring an additional 11,411 shares in the last quarter. Integrated Advisors Network LLC acquired a new stake in Humacyte during the 3rd quarter worth $151,000. Finally, R Squared Ltd raised its stake in Humacyte by 140.5% during the 1st quarter. R Squared Ltd now owns 62,911 shares of the company’s stock worth $38,000 after acquiring an additional 36,758 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.